Enjoy complimentary customisation on priority with our Enterprise License!
The antimicrobial therapeutics market is estimated to grow at a CAGR of 5.63% between 2023 and 2027. The size of the market is forecast to increase by USD 51.4 billion. The growth of the market depends on several factors, including recent drug approvals and a robust pipeline, initiatives from government agencies in the pharmaceutical industry, and rising awareness about microbial diseases.
This report extensively covers market segmentation by application (antiviral, antibacterial, antifungal, and antiparasitic), end-user (pharmacies, hospitals and clinics, and research and academic institutes), and Geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, Download Report Sample
The initiatives from government agencies in the pharmaceutical industry are notably driving the market growth, although factors such as the increased availability of generic drugs may hamper the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Antimicrobial Therapeutics Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc.- The company conducts research and development, manufacturing, commercialization and offers innovative medicines and therapies globally. The company offers azactam injection which is used as medicine to treat symptoms of bacterial infections that occur in the blood and urinary tract.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the antiviral segment will be significant during the forecast period. During the forecast period, the antiviral segment is expected to grow moderately. The segment is driven by the increasing prevalence of viral infections such as influenza, hepatitis, COVID-19, and HIV/AIDS. Furthermore, the emergence of pandemic diseases such as COVID-19 increased demand for antiviral drugs, as remdesivir was being evaluated as one of the molecules for the treatment of COVID-19. As a result, the global outbreak of viral diseases is expected to contribute to market growth during the forecast period.
Get a glance at the market contribution of various segments Request a PDF Sample
The antiviral segment was valued at USD 63.75 billion in 2017 and continued to grow until 2021. The robust pipeline of antiviral drugs is one of the major factors driving the market. Increased antiviral drug use results in the development of pipeline drugs and novel therapies with novel targets and mechanisms of action. For instance, Immune Response BioPharma's (Immune Response) REMUNE is in Phase II clinical trials for the treatment of HIV/AIDS in paediatric patients. Furthermore, Abivax SA (Abivax) developed ABX464 for the treatment of HIV. It is a small oral molecule that prevents HIV replication by removing viral reservoirs and lowering viral load in HIV patients. As a result, the market in focus is expected to experience accelerated growth momentum during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The rise in the number of microbial diseases in countries such as the United States and Canada is a major factor driving the North American market. The Centers for Disease Control and Prevention (CDC) estimated in March 2023 that influenza would affect approximately 26 million people in the United States in 2022-2023. Furthermore, in many countries, HIV/AIDS is the leading cause of death. Furthermore, the COVID-19 outbreak in the region affected a large proportion of the population and resulted in the highest number of deaths in 2020.
During the forecast period, the presence of strong reimbursement schemes for the treatment of deadly microbial diseases in the US is expected to drive the market. For instance, the Vaccines for Children (VFC) programme provides free vaccines for children who are uninsured, Medicaid-eligible, and under-insured. The Centers for Medicare and Medicaid Services in the United States reimburses all elderly patients with microbial infections such as HIV.
This report forecasts the contribution of all the segments to the growth of the market. In addition, we have included the COVID-19 impact and the recovery strategies for each segment. The COVID-19 pandemic in 2020 had a significant impact on many nations in North America. The healthcare industry was severely affected by COVID-19, which led to significant disruptions throughout the supply chain from the acquisition of raw materials to production and delivery in 2020. To prevent the virus from spreading, several countries around the world implemented widespread measures such as temporary closures of non-essential businesses, event cancellations, travel restrictions, quarantines, and other disruptive actions. All of these factors contributed to the closure of manufacturing units in several industries, including automotive and medical equipment.
However, due to the availability of COVID-19 vaccines and vaccination drives conducted by governments in various countries such as the United States, Canada, and Mexico, business and industrial activities resumed in 2021 with the relaxation of stringent lockdown restrictions. The growing need for new therapeutics to treat microbial disease, rising antimicrobial medicine adoption, and rising R&D expenditure in pharmaceutical companies are expected to influence the growth of the antimicrobial therapeutics market in North America in 2022, which is expected to grow during the forecast period.
The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
The reports categorize the global antimicrobial therapeutics market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in research and development or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.
|
Antimicrobial Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
167 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.63% |
|
Market growth 2023-2027 |
USD 51.4 billion |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
5.22 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 38% |
|
Key countries |
US, Germany, France, China, and Japan |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Astellas Pharma Inc., Bavarian Nordic AS, Biocidium Biopharmaceuticals Inc., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., CSL Ltd., Emergent BioSolutions Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson Services Inc., Merck and Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Novavax Inc., Pfizer Inc., Sanofi SA, and Wockhardt Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
